Halozyme Therapeutics (HALO) just posted stronger-than-expected numbers for the first quarter of 2025. The company reported earnings of $1.11 per share, beating the estimate of $0.95.

That’s a solid jump from $0.79 per share a year ago. On the revenue side, Halozyme brought in $264.86 million, topping expectations by almost 11 percent.

S&P’s Down, Yet HALO’s Up

This makes it the fourth quarter in a row that Halozyme has beaten both revenue and earnings estimates. The company seems to be building a solid track record of steady performance, and the market has noticed. Since the start of the year, HALO shares are up more than 26 percent.

That’s a big win considering the S&P 500 has fallen about 4 percent over the same period.

The company is part of the biomedical and genetics sector, which is currently ranked in the top 31 percent of all industries tracked by Zacks. Investors tend to watch this sector closely, and consistent earnings beats like this help Halozyme stand out.

Q2 Predictions

Looking ahead, Wall Street is expecting Halozyme to post $1.16 per share in earnings next quarter, with revenue coming in at around $280 million. For the full year, expectations sit at $5.13 EPS and over $1.2 billion in revenue.

Analysts haven’t shifted their ratings much after this report. HALO currently holds a Zacks Rank of 3, which means it’s expected to perform in line with the market in the near term.

Still, with strong numbers and a stock price on the rise, many investors are keeping it on their radar.

Halozyme may not be the flashiest name in biotech, but right now it’s one of the most consistent. And that’s something investors are starting to pay attention to.